NCT04232345View on ClinicalTrials.gov

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

March 11, 2021

Study Completion Date

March 11, 2021

Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
DRUG

AZD4831

Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.

DRUG

Placebo

Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.

Trial Locations (1)

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY